BOULDER, Colo.–(BUSINESS WIRE)–Enveda Biosciences, a biotechnology company discovering new medicines from natural sources, released the details of one of its foundational AI models, MS2Mol, in a pre-print posted on ChemRxiv. MS2Mol is designed to predict the structure of metabolites, which are the building blocks and breakdown products of the cell. Despite their essential role in all cell processes, it is estimated that less than 1% of all naturally-occurring metabolites are known to science.
Click here to view original post
News
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer
CHICAGO and FORT WORTH, Texas, Feb. 25, 2025 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers […]
News
Ozempic for Weight Loss: What You Need to Know
Whether online or at the grocery store check-out lane, it’s hard to avoid news of a celebrity’s dramatic weight loss and the speculation as to whether he or she is taking a new weight-loss medication. […]
News
Submit Your Best Science: ISHLT Accepting Abstracts for its 2023 Annual Meeting
CHICAGO, Aug. 1, 2022 /PRNewswire/ — The International Society for Heart and Lung Transplantation (ISHLT) has opened abstract submissions for its 43rd Annual Meeting & Scientific Sessions in Denver, Colorado on 19-22 April, 2023. This […]
